Developing Next-Generation Therapies For Breast Cancer Patients

Enrolling breast cancer trials means recruiting across HR+, HER2+, HER2-low, and triple-negative subtypes simultaneously, each with distinct molecular testing requirements, prior therapy lines, and site-level expertise needs. This fact sheet details a track record built specifically around that complexity: 40+ breast cancer studies, 4,300+ patients enrolled, and 350+ sites spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East/North Africa, supporting modalities from antibody-drug conjugates and bispecifics to CAR T and cancer vaccines.

The sheet breaks down how biomarker-driven identification, competitive site landscapes, and inconsistent standards of care across regions shape enrollment strategy, and how an oncology-dedicated team with 11+ years of average experience and 90%+ retention translates into consistent study execution from early-phase through registration. For sponsors weighing where enrollment risk and timeline pressure are most likely to surface in a breast cancer program, this overview offers a way to benchmark trial design and site strategy against experience gained across dozens of comparable studies.